Recon Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition byJosh SandbergJanuary 16, 2024
Financial Top Stories Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash byJosh SandbergJune 23, 2023
Recon Conformis Announces First Procedure Performed Using New Actera™ Hip System byChris StewartNovember 29, 2022
Recon Regulatory Top Stories Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration byJosh SandbergSeptember 14, 2022
Recon Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants byJosh SandbergAugust 2, 2022
Recon New Clinical Study Finds Bilateral Knee Patients Prefer Conformis’ Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1 byJosh SandbergFebruary 28, 2022
Financial Conformis, Inc. Provides Business Update and Initial Expectations for 2022 byChris StewartJanuary 6, 2022
